Manganese‐Modified Aluminum Adjuvant Enhances both Humoral and Cellular Immune Responses

Abstract

Abstract Aluminum adjuvants remain the most commonly used vaccine adjuvants. Being rather effective in triggering humoral immunity, however, aluminum adjuvants usually show limited abilities in activating cellular immunities. Herein, by adding manganese ions during the preparation of aluminum adjuvant, a manganese‐modified aluminum (Mn‐Al) adjuvant is obtained, which can effectively stimulate both humoral and cellular immune responses. Such Mn‐Al adjuvant can enhance antigen adsorption and promote antigen internalization by dendritic cells (DCs). Subsequently, the released Mn 2+ can activate the cyclic guanosine monophosphate–adenosine monophosphate synthase‐stimulator of interferon genes pathway to further promote DC activation. When combines with the model antigen ovalbumin (OVA), the Mn‐Al‐adjuvantes vaccine can induce high levels of antigen‐specific antibody titers and high proportions of antigen‐specific cytotoxic T cells in vivo. Moreover, the Mn‐Al‐adjuvanted vaccine elicited stronger antigen‐specific humoral and cellular immune responses than high‐dose of the aluminum‐based adjuvant. Additionally, immunization of mice with OVA in the presence of the Mn‐Al adjuvant significantly inhibited the growth of B16‐OVA tumors. Furthermore, when formulated with human papillomavirus antigens, Mn‐Al‐adjuvanted vaccines show better in vivo vaccination performance than aluminum‐adjuvanted vaccines. Therefore, the manganese‐modified aluminum adjuvant may thus become a new vaccine adjuvant with the potential to replace conventional aluminum adjuvants.